ATNM Valuation

Actinium Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.790

-0.03(-1.648%)1D

Overview
Forecast
Valuation
Earnings

ATNM Relative Valuation

ATNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATNM is overvalued; if below, it's undervalued.

Historical Valuation

Actinium Pharmaceuticals Inc (ATNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.38. The fair price of Actinium Pharmaceuticals Inc (ATNM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.79 USD , Actinium Pharmaceuticals Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.79

Fair

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.21

P/B

Median3y

3.12

Median5y

2.75

-57.03

FCF Yield

Median3y

-31.54

Median5y

-24.79

Competitors Valuation Multiple

The average P/S ratio for ATNM's competitors is 34.55, providing a benchmark for relative valuation. Actinium Pharmaceuticals Inc Corp (ATNM) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATNM.A

Actinium Pharmaceuticals Inc

Loss

Average P/S: 34.55

55.84M